نتایج جستجو برای: fcγriiia

تعداد نتایج: 216  

Journal: :Journal for ImmunoTherapy of Cancer 2021

Background Rescue of exhausted T cell immunity through the inhibition PD-1/PD-L1 interaction is a pillar immunotherapeutic anti-PD-1 monoclonal antibodies (mAbs), as Nivolumab and Pembrolizumab. Despite IgG4 subclass, mAbs can bind different FcγRs trigger immunosuppressive activity in FcR-expressing myeloid cells. This effect evident when engage soluble PD-1 (sPD-1) forming stable sPD-1-antiPD-...

Journal: :Blood 2016
Andrzej Jakubowiak Massimo Offidani Brigitte Pégourie Javier De La Rubia Laurent Garderet Kamel Laribi Alberto Bosi Roberto Marasca Jacob Laubach Ann Mohrbacher Angelo Michele Carella Anil K Singhal L Claire Tsao Mark Lynch Eric Bleickardt Ying-Ming Jou Michael Robbins Antonio Palumbo

In this proof-of-concept, open-label, phase 2 study, patients with relapsed/refractory multiple myeloma (RRMM) received elotuzumab with bortezomib and dexamethasone (EBd) or bortezomib and dexamethasone (Bd) until disease progression/unacceptable toxicity. Primary endpoint was progression-free survival (PFS); secondary/exploratory endpoints included overall response rate (ORR) and overall survi...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Andres Forero-Torres Sven de Vos Brad L Pohlman Maksim Pashkevich Damien M Cronier Nam H Dang Susan P Carpenter Barrett W Allan James G Nelson Christopher A Slapak Mitchell R Smith Brian K Link James E Wooldridge Kristen N Ganjoo

PURPOSE AME-133v is a humanized monoclonal antibody engineered to have increased affinity to CD20 and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) better than rituximab. Safety, pharmacokinetics, and efficacy were assessed in a phase 1/2 trial in patients with previously treated follicular lymphoma (FL). PATIENTS AND METHODS AME-133v was characterized in vitro by ADCC and cell...

2017
Bong-Ha Shin Shili Ge James Mirocha Stanley C. Jordan Mieko Toyoda

BACKGROUND We previously demonstrated that natural killer (NK) cells activated via FcγRIIIa (CD16) interactions with anti-HLA antibodies binding to peripheral blood mononuclear cells (PBMCs) in the in vitro antibody-dependent cellular cytotoxicity (ADCC) assay produced IFNγ. Here we investigate if other CD16 bearing cells are responsive to alloantigen via alloantibody in the in vitro ADCC and i...

2017
Tik Nga Tong Donald R. Branch

Although originally developed for predicting transfusion outcomes of serologically incompatible blood, the monocyte monolayer assay (MMA) is a highly versatile in vitro assay that can be modified to examine different aspects of antibody and Fcγ receptor (FcγR)-mediated phagocytosis in both research and clinical settings. The assay utilizes adherent monocytes from peripheral blood mononuclear ce...

2015
Stephan Klöss Nicole Chambron Tanja Gardlowski Sandra Weil Joachim Koch Ruth Esser Elke Pogge von Strandmann Michael A. Morgan Lubomir Arseniev Oliver Seitz Ulrike Köhl

Immunosuppressive factors, such as soluble major histocompatibility complex class I chain-related peptide A (sMICA) and transforming growth factor beta 1 (TGF-β1), are involved in tumor immune escape mechanisms (TIEMs) exhibited by head and neck squamous cell carcinomas (HNSCCs) and may represent opportunities for therapeutic intervention. In order to overcome TIEMs, we investigated the antibod...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید